The global Antisense & RNAi Therapeutics market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
By Market Verdors:
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
By Types:
RNA interference
SiRNA
MiRNA
Antisense RNA
By Applications:
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2017-2028 & Sales with a thorough analysis of the market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2017-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Antisense & RNAi Therapeutics Market Size Analysis from 2023 to 2028
1.5.1 Global Antisense & RNAi Therapeutics Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Antisense & RNAi Therapeutics Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Antisense & RNAi Therapeutics Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Antisense & RNAi Therapeutics Industry Impact
Chapter 2 Global Antisense & RNAi Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antisense & RNAi Therapeutics (Volume and Value) by Type
2.1.1 Global Antisense & RNAi Therapeutics Consumption and Market Share by Type (2017-2022)
2.1.2 Global Antisense & RNAi Therapeutics Revenue and Market Share by Type (2017-2022)
2.2 Global Antisense & RNAi Therapeutics (Volume and Value) by Application
2.2.1 Global Antisense & RNAi Therapeutics Consumption and Market Share by Application (2017-2022)
2.2.2 Global Antisense & RNAi Therapeutics Revenue and Market Share by Application (2017-2022)
2.3 Global Antisense & RNAi Therapeutics (Volume and Value) by Regions
2.3.1 Global Antisense & RNAi Therapeutics Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Antisense & RNAi Therapeutics Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Antisense & RNAi Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Antisense & RNAi Therapeutics Consumption by Regions (2017-2022)
4.2 North America Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.10 South America Antisense & RNAi Therapeutics Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Antisense & RNAi Therapeutics Market Analysis
5.1 North America Antisense & RNAi Therapeutics Consumption and Value Analysis
5.1.1 North America Antisense & RNAi Therapeutics Market Under COVID-19
5.2 North America Antisense & RNAi Therapeutics Consumption Volume by Types
5.3 North America Antisense & RNAi Therapeutics Consumption Structure by Application
5.4 North America Antisense & RNAi Therapeutics Consumption by Top Countries
5.4.1 United States Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
5.4.2 Canada Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
5.4.3 Mexico Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 6 East Asia Antisense & RNAi Therapeutics Market Analysis
6.1 East Asia Antisense & RNAi Therapeutics Consumption and Value Analysis
6.1.1 East Asia Antisense & RNAi Therapeutics Market Under COVID-19
6.2 East Asia Antisense & RNAi Therapeutics Consumption Volume by Types
6.3 East Asia Antisense & RNAi Therapeutics Consumption Structure by Application
6.4 East Asia Antisense & RNAi Therapeutics Consumption by Top Countries
6.4.1 China Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
6.4.2 Japan Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
6.4.3 South Korea Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 7 Europe Antisense & RNAi Therapeutics Market Analysis
7.1 Europe Antisense & RNAi Therapeutics Consumption and Value Analysis
7.1.1 Europe Antisense & RNAi Therapeutics Market Under COVID-19
7.2 Europe Antisense & RNAi Therapeutics Consumption Volume by Types
7.3 Europe Antisense & RNAi Therapeutics Consumption Structure by Application
7.4 Europe Antisense & RNAi Therapeutics Consumption by Top Countries
7.4.1 Germany Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.2 UK Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.3 France Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.4 Italy Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.5 Russia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.6 Spain Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.7 Netherlands Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.8 Switzerland Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
7.4.9 Poland Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 8 South Asia Antisense & RNAi Therapeutics Market Analysis
8.1 South Asia Antisense & RNAi Therapeutics Consumption and Value Analysis
8.1.1 South Asia Antisense & RNAi Therapeutics Market Under COVID-19
8.2 South Asia Antisense & RNAi Therapeutics Consumption Volume by Types
8.3 South Asia Antisense & RNAi Therapeutics Consumption Structure by Application
8.4 South Asia Antisense & RNAi Therapeutics Consumption by Top Countries
8.4.1 India Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
8.4.2 Pakistan Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Antisense & RNAi Therapeutics Market Analysis
9.1 Southeast Asia Antisense & RNAi Therapeutics Consumption and Value Analysis
9.1.1 Southeast Asia Antisense & RNAi Therapeutics Market Under COVID-19
9.2 Southeast Asia Antisense & RNAi Therapeutics Consumption Volume by Types
9.3 Southeast Asia Antisense & RNAi Therapeutics Consumption Structure by Application
9.4 Southeast Asia Antisense & RNAi Therapeutics Consumption by Top Countries
9.4.1 Indonesia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.2 Thailand Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.3 Singapore Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.4 Malaysia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.5 Philippines Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.6 Vietnam Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
9.4.7 Myanmar Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 10 Middle East Antisense & RNAi Therapeutics Market Analysis
10.1 Middle East Antisense & RNAi Therapeutics Consumption and Value Analysis
10.1.1 Middle East Antisense & RNAi Therapeutics Market Under COVID-19
10.2 Middle East Antisense & RNAi Therapeutics Consumption Volume by Types
10.3 Middle East Antisense & RNAi Therapeutics Consumption Structure by Application
10.4 Middle East Antisense & RNAi Therapeutics Consumption by Top Countries
10.4.1 Turkey Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.3 Iran Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.5 Israel Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.6 Iraq Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.7 Qatar Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.8 Kuwait Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
10.4.9 Oman Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 11 Africa Antisense & RNAi Therapeutics Market Analysis
11.1 Africa Antisense & RNAi Therapeutics Consumption and Value Analysis
11.1.1 Africa Antisense & RNAi Therapeutics Market Under COVID-19
11.2 Africa Antisense & RNAi Therapeutics Consumption Volume by Types
11.3 Africa Antisense & RNAi Therapeutics Consumption Structure by Application
11.4 Africa Antisense & RNAi Therapeutics Consumption by Top Countries
11.4.1 Nigeria Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
11.4.2 South Africa Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
11.4.3 Egypt Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
11.4.4 Algeria Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
11.4.5 Morocco Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 12 Oceania Antisense & RNAi Therapeutics Market Analysis
12.1 Oceania Antisense & RNAi Therapeutics Consumption and Value Analysis
12.2 Oceania Antisense & RNAi Therapeutics Consumption Volume by Types
12.3 Oceania Antisense & RNAi Therapeutics Consumption Structure by Application
12.4 Oceania Antisense & RNAi Therapeutics Consumption by Top Countries
12.4.1 Australia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
12.4.2 New Zealand Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 13 South America Antisense & RNAi Therapeutics Market Analysis
13.1 South America Antisense & RNAi Therapeutics Consumption and Value Analysis
13.1.1 South America Antisense & RNAi Therapeutics Market Under COVID-19
13.2 South America Antisense & RNAi Therapeutics Consumption Volume by Types
13.3 South America Antisense & RNAi Therapeutics Consumption Structure by Application
13.4 South America Antisense & RNAi Therapeutics Consumption Volume by Major Countries
13.4.1 Brazil Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.2 Argentina Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.3 Columbia Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.4 Chile Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.5 Venezuela Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.6 Peru Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
13.4.8 Ecuador Antisense & RNAi Therapeutics Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Antisense & RNAi Therapeutics Business
14.1 Glaxo Smith Kline
14.1.1 Glaxo Smith Kline Company Profile
14.1.2 Glaxo Smith Kline Antisense & RNAi Therapeutics Product Specification
14.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Sanofi Aventis / Genzyme
14.2.1 Sanofi Aventis / Genzyme Company Profile
14.2.2 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product Specification
14.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
14.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Profile
14.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Arbutus Biopharma Ltd.
14.4.1 Arbutus Biopharma Ltd. Company Profile
14.4.2 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product Specification
14.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Silence Therapeutics
14.5.1 Silence Therapeutics Company Profile
14.5.2 Silence Therapeutics Antisense & RNAi Therapeutics Product Specification
14.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Bio-Path Holdings Inc.
14.6.1 Bio-Path Holdings Inc. Company Profile
14.6.2 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product Specification
14.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Calando Pharmaceuticals
14.7.1 Calando Pharmaceuticals Company Profile
14.7.2 Calando Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 ICo Therapeutics
14.8.1 ICo Therapeutics Company Profile
14.8.2 ICo Therapeutics Antisense & RNAi Therapeutics Product Specification
14.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Quark Pharmaceuticals
14.9.1 Quark Pharmaceuticals Company Profile
14.9.2 Quark Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Rexhan Pharmaceuticals
14.10.1 Rexhan Pharmaceuticals Company Profile
14.10.2 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 Biomarin/Prosensa
14.11.1 Biomarin/Prosensa Company Profile
14.11.2 Biomarin/Prosensa Antisense & RNAi Therapeutics Product Specification
14.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 Regulus Therapeutics
14.12.1 Regulus Therapeutics Company Profile
14.12.2 Regulus Therapeutics Antisense & RNAi Therapeutics Product Specification
14.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Rxi Pharmaceuticals
14.13.1 Rxi Pharmaceuticals Company Profile
14.13.2 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.14 Silenseed
14.14.1 Silenseed Company Profile
14.14.2 Silenseed Antisense & RNAi Therapeutics Product Specification
14.14.3 Silenseed Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.15 Dicerna Pharmaceuticals
14.15.1 Dicerna Pharmaceuticals Company Profile
14.15.2 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product Specification
14.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.16 Sirnaomics Inc.
14.16.1 Sirnaomics Inc. Company Profile
14.16.2 Sirnaomics Inc. Antisense & RNAi Therapeutics Product Specification
14.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Antisense & RNAi Therapeutics Market Forecast (2023-2028)
15.1 Global Antisense & RNAi Therapeutics Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Antisense & RNAi Therapeutics Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Antisense & RNAi Therapeutics Value and Growth Rate Forecast (2023-2028)
15.2 Global Antisense & RNAi Therapeutics Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Antisense & RNAi Therapeutics Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Antisense & RNAi Therapeutics Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Antisense & RNAi Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Antisense & RNAi Therapeutics Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Antisense & RNAi Therapeutics Consumption Forecast by Type (2023-2028)
15.3.2 Global Antisense & RNAi Therapeutics Revenue Forecast by Type (2023-2028)
15.3.3 Global Antisense & RNAi Therapeutics Price Forecast by Type (2023-2028)
15.4 Global Antisense & RNAi Therapeutics Consumption Volume Forecast by Application (2023-2028)
15.5 Antisense & RNAi Therapeutics Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
| Price : US$ 2450 |
Date : Jan 2024 |
| Category : Electronics |
Pages : 274 |
| Price : US$ 3500 |
Date : Apr 2024 |
| Category : Electronics |
Pages : 129 |
Request Sample 
Request Discount 
Inquire Before Buy
